Lv11
16 积分 2025-04-06 加入
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
2小时前
已完结
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
2小时前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
9天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
11天前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
11天前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
11天前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
11天前
已完结
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
14天前
已完结
Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
14天前
已完结
Lung cancer
20天前
已完结
皖公网安备34019202002308